Comment on: Jones et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care 2011;34:828–837 | Zendy

Alper Sönmez | Zendy; Abdullah Taşlıpınar | Zendy; Serkan Tapan | Zendy; Muhittin Serdar | Zendy

Open Access

Comment on: Jones et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care 2011;34:828–837

Author(s) -

Alper Sönmez,

Abdullah Taşlıpınar,

Serkan Tapan,

Muhittin Serdar

Publication year - 2011

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc11-1292

Subject(s) - medicine , diabetes mellitus , type 2 diabetes , metabolic syndrome , testosterone replacement , testosterone (patch) , endocrinology , type 1 diabetes , hormone , androgen

The results of the TIMES2 study indicate that a transdermal testosterone regiment improves glucose control, insulin resistance, lipid parameters, and sexual health in hypogonadal men with type 2 diabetes and metabolic syndrome (1). The idea of improving metabolic profile with a bonus of increased libido must be charming for all the physicians working in the field. However, after winnowing the busy data, we noticed several critical problems with the interpretation of the results.The effects of testosterone on glycemic control and insulin sensitivity seem to be overemphasized. The abstract states a better glycemic control in the 9th month of testosterone treatment. Yet, it is evident that the HbA1c levels do …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research